Urogen Pharma Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
URGN Nasdaq 8731 https://www.urogen.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Urogen Pharma Ltd

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jun 9th, 2023 12:00 pm
UroGen Pharma to Present at Upcoming Investor Conferences - Jun 2nd, 2023 12:00 pm
With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns - May 22nd, 2023 5:18 pm
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript - May 16th, 2023 4:13 pm
Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates - May 11th, 2023 1:15 pm
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments - May 11th, 2023 12:00 pm
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023 - May 4th, 2023 12:00 pm
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline - May 2nd, 2023 2:02 pm
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation - May 1st, 2023 6:00 pm
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis - Apr 30th, 2023 12:00 pm
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference - Apr 25th, 2023 12:00 pm
UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift Shares - Apr 18th, 2023 4:16 pm
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call Transcript - Mar 18th, 2023 6:06 am
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates - Mar 16th, 2023 1:15 pm
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments - Mar 16th, 2023 12:00 pm
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023 - Mar 9th, 2023 9:00 pm
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 6th, 2023 1:00 pm
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates - Feb 27th, 2023 1:15 pm
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer - Feb 15th, 2023 2:06 pm
UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future - Feb 6th, 2023 10:33 am